Q5148 Filgrastim-txid (nypozi) - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Filgrastim-txid (nypozi)

Brand Name:

Nypozi

Strength:

1 microgram

HCPCS:

Q5148

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Colony-Stimulating Factor

Oral (Y/N):

No

FDA Approval Year:

2024

FDA Discontinuation Year:

CMS Effective Date:

March 26, 2025

CMS Discontinuation Date:

Status:

In Use